NASDAQ:ORGS - Orgenesis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.37
▲ +0.05 (1.51%)

This chart shows the closing price for ORGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orgenesis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORGS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Orgenesis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.37.

This chart shows the closing price for ORGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Orgenesis. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2019BenchmarkInitiated CoverageBuy$9.00 ➝ $9.00Low
12/20/2018Dawson JamesReiterated RatingBuyHigh
12/20/2018Dawson JamesInitiated CoverageBuy ➝ BuyMedium
(Data available from 12/8/2016 forward)

News Sentiment Rating

0.87 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/9/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/8/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/8/2021

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Orgenesis logo
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Read More

Today's Range

Now: $3.37
Low: $3.21
High: $3.38

50 Day Range

MA: $4.29
Low: $2.89
High: $5.08

52 Week Range

Now: $3.37
Low: $2.88
High: $8.30

Volume

88,833 shs

Average Volume

207,816 shs

Market Capitalization

$81.81 million

P/E Ratio

155.50

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Orgenesis?

The following Wall Street analysts have issued stock ratings on Orgenesis in the last year:
View the latest analyst ratings for ORGS.

What is the current price target for Orgenesis?

0 Wall Street analysts have set twelve-month price targets for Orgenesis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Orgenesis in the next year.
View the latest price targets for ORGS.

What is the current consensus analyst rating for Orgenesis?

Orgenesis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ORGS.

How do I contact Orgenesis' investor relations team?

Orgenesis' physical mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company's listed phone number is (480) 659-6404 and its investor relations email address is [email protected] The official website for Orgenesis is www.orgenesis.com.